Clinical Discussion Series

First-line Treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early- versus Advanced-Stage Disease
First-line Treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early- versus Advanced-Stage Disease
CME, CPE
Andrew M. Evens, DO, MSc, FACP
Release Date: April 27, 2016
Expiration Date: April 27, 2017

Dr. Andrew Evens will address the critical differences in therapeutic strategies for patients who are diagnosed with early stage HL versus those who are diagnosed at an advanced stage. Through a practical review of the newest regimens and strategies, Dr. Evens will discuss the latest evidence supporting the differential use of each as first-line therapy for the newly diagnosed HL patient.

To download the accompanying e-Transcript for reference purposes only click here.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved